[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350281-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350281-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mtor-inhibition-promotes-atra-induced-cancer-cell-differentiation-by-overcoming-a-metabolic-hyperactive-state","mTOR inhibition promotes ATRA-induced cancer cell differentiation by overcoming a metabolic hyperactive state","","All-trans retinoic acid (ATRA), derived from vitamin A, strongly promotes maturation in acute promyelocytic leukemia, yet its effect is weakened in non-APL acute myeloid leukemia and solid tumors. The study dissects ATRA resistance and finds that ATRA triggers both myeloid differentiation programs and a hyperactive metabolic state that blocks terminal maturation. mTOR inhibition with PP242 suppresses the metabolic surge, reroutes transcription toward effective differentiation, and improves viability, especially in RAS-mutant settings.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mtor-inhibition-promotes-atra-induced-cancer-cell-differentiation-by-overcoming-a-metabolic-hyperactive-state/350281/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mtor-inhibition-promotes-atra-induced-cancer-cell-differentiation-by-overcoming-a-metabolic-hyperactive-state/350281.png","ImageObject",300,407,{"name":42,"@type":43},"Putri","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why does ATRA differentiation fail in non-APL AML and solid tumors?","Question",{"text":63,"@type":64},"ATRA triggers myeloid differentiation while simultaneously inducing a hyperactive metabolic state that impedes terminal maturation. This metabolic barrier reduces the effectiveness of ATRA outside APL contexts.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What experimental strategy was used to uncover the resistance mechanisms?",{"text":68,"@type":64},"The study used integrated high-throughput sequencing approaches, including single-cell multiomics, DRUG-seq, bulk RNA-seq, ATAC-seq, and CUT&Tag, combined with functional validation such as flow cytometry, siRNA transfection, Western blotting, and CDX models.",{"name":70,"@type":61,"acceptedAnswer":71},"How does inhibiting mTOR help overcome ATRA resistance?",{"text":72,"@type":64},"Pharmacological inhibition of the mTOR pathway with PP242 suppresses the ATRA-driven metabolic surge and redirects transcriptional output toward differentiation, resulting in improved maturation and reduced viability.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350281,1790668200,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962085571259,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Zhang et al. Journal of Translational Medicine (2026) 24:662  \n[https://doi.org/10.1186/s12967-026-08218-7](https://doi.org/10.1186/s12967-026-08218-7)  \nJournal of Translational Medicine  \nRESEARCH Open Access  \nmTOR inhibition promotes ATRA-induced cancer cell differentiation by overcoming a metabolic hyperactive state  \nLiuqingqing Zhang1†, Guiqiyang Xiang1†, Ping Zhu1†, Shuting Yu1, Fangying Jiang1, Shuai Wang1, Jinzeng Wang1, Yao Dai1, Shengyue Wang1, Yun Tan1, Han Liu 1* and Feng Liu 1*  \nAbstract  \nBackground All-trans retinoic acid (ATRA), a derivative of vitamin A, potently induces cell maturation in acute promyelocytic leukemia (APL) . However, this therapeutic effect is attenuated or absent in non-APL acute myeloid leukemia (AML) and solid tumors. This study aims to elucidate the mechanisms underlying ATRA resistance and identify strategies to overcome it.  \nMethods Integrated high-throughput sequencing—including single-cell multiomics, digital RNA with pertUrbation of genes (DRUG)-seq, bulk RNA-seq, ATAC-seq and CUT&Tag—was performed on AML and solid tumor cell lines treated with ATRA and the mTOR inhibitor PP242 . Functional validation was conducted using flow cytometry, siRNA transfection, morphological assessment, Western Blotting and cell line derived xenografts (CDX) . Pan-cancer analysis leveraged the Tahoe-100 M pharmacological perturbation dataset to assess metabolic responses across 50 cancer cell lines.  \nResults ATRA simultaneously activates myeloid differentiation programs and a hyperactive metabolic state that impedes terminal maturation in non-APL AML cells. Pharmacological inhibition of the mechanistic target of themTOR pathway with PP242 suppresses this metabolic surge and redirects transcriptional output toward effective differentiation. The Tahoe-100 M analysis reveals that cancers harboring oncogenic RAS mutations exhibit heightened metabolic responsiveness to ATRA, a vulnerability confirmed in RAS-mutant lung and colon carcinoma cell lines. In these models, ATRA and PP242 synergistically promotes cell maturation and reduces viability.  \nConclusions These findings uncover a conserved metabolic barrier that limits ATRA-induced differentiation beyond APL. mTOR acts as a critical node governing the balance between pro-differentiation and pro-metabolic signals.  \nCo-targeting mTOR overcomes this barrier, particularly in RAS-mutant malignancies, providing a genotype-informed rationale for extending differentiation therapy to broader cancer contexts.  \n†Liuqingqing Zhang, Guiqiyang Xiang, and Ping Zhu contributed equally.  \n*Correspondence: Han Liu [liuhan68@sjtu.edu.cn](liuhan68@sjtu.edu.cn)[ ](liuhan68@sjtu.edu.cn)Feng Liu[lf12034@rjh.com.cn](lf12034@rjh.com.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nZhang et al. Journal of Translational Med","cbCaifm3OT5TEM0J","https://ap.wps.com/l/cbCaifm3OT5TEM0J","pdf",16337727,21,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords\n# Background","[{\"question\":\"Why does ATRA differentiation fail in non-APL AML and solid tumors?\",\"answer\":\"ATRA triggers myeloid differentiation while simultaneously inducing a hyperactive metabolic state that impedes terminal maturation. This metabolic barrier reduces the effectiveness of ATRA outside APL contexts.\"},{\"question\":\"What experimental strategy was used to uncover the resistance mechanisms?\",\"answer\":\"The study used integrated high-throughput sequencing approaches, including single-cell multiomics, DRUG-seq, bulk RNA-seq, ATAC-seq, and CUT\\u0026Tag, combined with functional validation such as flow cytometry, siRNA transfection, Western blotting, and CDX models.\"},{\"question\":\"How does inhibiting mTOR help overcome ATRA resistance?\",\"answer\":\"Pharmacological inhibition of the mTOR pathway with PP242 suppresses the ATRA-driven metabolic surge and redirects transcriptional output toward differentiation, resulting in improved maturation and reduced viability.\"}]","mTOR inhibition promotes ATRA-induced cancer cell differentiation by overcoming a metabolic hyperactive state | PDF",1790088207,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eaf130ed1f8d3e897707ab819801e19e.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9945001116669b93783630a1b4cb9c0c.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/579dd12fb6bbf465c2c2f6cf064023c6.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8bca8e0962e5ca2ddd29e4d9026287d.webp",980,1306]